Byetta®
Manufacturer:
Amylin Pharmaceuticals, Inc. & Eli Lilly & Co.
More Information
|
The FDA is alerting health care professionals that
Byetta® may be associated with acute pancreatitis in some patients.
Byetta® is administered by a twice a day injection to treat type two
diabetes. More than 700,000 patients have used the drug since it was
released in 2005.
The FDA has reviewed 30 reports of individuals taking
Byetta® and developed acute pancreatitis. 21 of those
patients were hospitalized, five of them with serious complications.
22 of these individuals improved after discontinuing the drug.
Symptoms of acute pancreatitis are persistent and
severe abdominal pain possibly accompanied by vomiting.
If you or someone you know has sustained acute
pancreatitis or other damages while taking Byetta®, please contact us to
discuss your rights,
www.816LAWFIRM.com or
call us toll-free at 1-800-305-7552.
Call Peterson & Associates today &
Click Here.
|
| Byetta |
For more information:
Pharmaceutical Litigation
Prescription
Injury FAQs
Pharmaceutical Legal Glossary
Recent Byetta Headlines
>> Amylin Rises on Optimism FDA Will Approve New Byetta - Bloomberg... - Tue, 26 Jan 2010
>> Alkermes Retains Neutral Rec - Analyst Blog - Benzinga... - Mon, 08 Feb 2010
>> Victoza may be a large step forward - Gerson Lehrman Group... - Mon, 08 Feb 2010
>> Byetta and Avandia combined in the treatment of type 2 diabetes - Exam... - Thu, 04 Feb 2010
>> Novo Nordisk Profit Little Changed on Higher Costs - BusinessWeek... - Tue, 02 Feb 2010
|
